Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

76P - Second interim analysis of INFINITY: A registry on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice

Date

10 Sep 2022

Session

Poster session 01

Topics

Clinical Research;  Cancer Registries;  Pathology/Molecular Biology;  Targeted Therapy;  Molecular Oncology;  Immunotherapy

Tumour Site

Presenters

Uwe Martens

Citation

Annals of Oncology (2022) 33 (suppl_7): S27-S54. 10.1016/annonc/annonc1037

Authors

U.M. Martens1, J. Schröder2, L. Sellmann3, M. Reiser4, S. Frank-Gleich5, T. Decker6, A. Schneeweiss7, M. Schuler8, S. Grebhardt9, S. Woerner10, S. Zacharias11, N.W. Marschner10, B. Kasenda12, C. Vannier10

Author affiliations

  • 1 Klinik Für Innere Medizin Iii: Hämatologie, Onkologie, Palliativmedizin, SLK-Kliniken Heilbronn GmbH, 74078 - Heilbronn/DE
  • 2 Hämatologie Und Onkologie, MVZ für Hämatologie und Onkologie in Mülheim an der Ruhr, 45468 - Mülheim/DE
  • 3 Hämatologie Und Onkologie, Praxis für Onkologie - Sellmann & Bartels, 41066 - Mönchengladbach/DE
  • 4 Hämatologie Und Onkologie, PIOH (Köln Zentrum) - Praxis Internistischer Onkologie und Hämatologie, 50674 - Köln/DE
  • 5 Hämatologie Und Onkologie, Gemeinschaftspraxis und Tagesklinik - Innere Medizin, Hämatologie, Onkologie, Gastroenterologie, Palliativmedizin, 06110 - Halle/Saale/DE
  • 6 Hämatologie Und Onkologie, Gemeinschaftspraxis für Hämatologie und Onkologie, 88212 - Ravensburg/DE
  • 7 Nationales Centrum Für Tumorerkrankungen, Universitätsklinikum und Deutsches Krebsforschungszentrum, 69115 - Heidelberg/DE
  • 8 Westdeutsches Tumorzentrum Essen, Universitätsklinikum Essen, 45147 - Essen/DE
  • 9 Clinical Operations, iOMEDICO AG, 79106 - Freiburg im Breisgau/DE
  • 10 Medical Oncology Department, iOMEDICO AG, 79106 - Freiburg im Breisgau/DE
  • 11 Biostatistics, iOMEDICO AG, 79106 - Freiburg im Breisgau/DE
  • 12 Medical Oncology Department, Universitatsspital Basel, 4031 - Basel/CH
More

Abstract 76P

Background

Biomarker-driven treatment decision-making has entered routine clinical practice, particularly for patients with advanced malignancies when no further standard therapies are available. INFINITY aims to systematically analyze this approach in routine clinical care.

Methods

INFINITY is a retrospective, observational study conducted at 100 sites in Germany (medical offices and hospitals). 500 patients with advanced solid tumors or hematological malignancies who received a non-standard targeted therapy (NSTT) based on a potentially actionable biomarker will be included. Details on patient and disease characteristics, treatment, outcome, physician’s decision-making, and molecular testing will be collected. We herein present results from the second interim analysis.

Results

From 30-April-2020 to 30-June-2021, 333 eligible patients from 61 sites were registered. Most patients were treated by office-based (hematologist-)oncologists (n=237, 71.2%). Median time from primary diagnosis to start of first NSTT was 22.5 months. The majority (n=216, 64.9%) had received ≥2 prior therapy lines. Most frequent cancer entities were colorectal (n=66, 19.8%), esophageal (n=22, 6.6%), breast and gastric cancer (n=20, 6.0% each). Most frequently applied NSTT substance classes were PD-(L)1 antibodies (n=157, 47.1%) and BRAF inhibitors (n=35, 10.5%). Accordingly, most frequent actionable biomarkers were PD-L1 status, microsatellite instable (MSI) status and BRAF gene alterations. For 212 pts, information to calculate the progression-free survival (PFS) ratio was available. A PFS ratio ≥1.3 was achieved in 27.8% (59/212) of patients in the total population, 24.7% (24/97) of patients with PD-(L)1 antibody therapy, and 24.1% (7/29) with BRAF inhibitor therapy. Median overall survival was 10.9 months in the total population, 11.5 months for patients with PD-(L)1 antibody therapy, and 8.1 months for patients with BRAF inhibitor therapy.

Conclusions

Most common biomarkers driving targeted therapies included PD-L1 expression, MSI status and BRAF gene alterations. Preliminary results suggest some potential benefit in approximately one quarter of patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

iOMEDICO.

Funding

Roche, Bristol Myers Squibb.

Disclosure

U.M. Martens: Financial Interests, Personal, Advisory Role: Roche, BMS, Pierre Fabre. T. Decker: Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Role: iOMEDICO. A. Schneeweiss: Financial Interests, Institutional, Research Grant: Celgene, Roche, AbbVie; Financial Interests, Personal, Other, Travel expenses: Celgene, Roche, Pfizer; Financial Interests, Personal, Other, Honoraria: Roche, Celgene, Pfizer, AstraZeneca, Novartis, MSD, Tesaro, Lilly, Seagen, Gilead, GSK, Bayer, Amgen, Pierre Fabre. M. Schuler: Financial Interests, Personal, Advisory Role: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Merck Serono, Novartis, Roche, Sanofi, Takeda; Financial Interests, Personal, Other, honoraria for CME presentations: Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis; Financial Interests, Institutional, Funding: AstraZeneca, Bristol Myers Squibb. N.W. Marschner: Financial Interests, Personal, Other, CEO: iOMEDICO; Financial Interests, Personal, Stocks/Shares: iOMEDICO; Financial Interests, Institutional, Funding: Roche, BMS. B. Kasenda: Financial Interests, Personal, Advisory Role: Astellas, Roche; Financial Interests, Personal, Stocks/Shares: BioNTech. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.